Spyre Therapeutics, Inc. (SYRE)
(Delayed Data from NSDQ)
$26.19 USD
-0.73 (-2.71%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $26.15 -0.04 (-0.15%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SYRE 26.19 -0.73(-2.71%)
Will SYRE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SYRE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SYRE
Here's What Could Help Spyre Therapeutics (SYRE) Maintain Its Recent Price Strength
Here's Why Spyre Therapeutics (SYRE) Could be Great Choice for a Bottom Fisher
SYRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SYRE
Commit To Buy Spyre Therapeutics At $20, Earn 15.7% Annualized Using Options
Spyre Therapeutics management to meet virtually with BTIG
Spyre Therapeutics management to meet virtually with BTIG
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
Spyre Therapeutics management to meet virtually with BTIG